Autres langues

08:35 Morning Meeting: La carrera desbocada de la IA deja rezagados
08:30 Morning Meeting: Das rasante KI-Tempo dünnt das Feld aus
08:15 AI's Breakneck Pace Thins the Ranks
06/10 European Stocks Close Higher in Tuesday Trading Amid Political Unrest in France, Spain
06/10 GSK-backed ViiV Healthcare's Cabenuva Meets Primary Endpoint in Late-stage HIV Trial
06/10 GSK celebrates "important insights" from Cabenuva study
06/10 GSK's ViiV Healthcare Says HIV Treatment Cabenuva's Latest Trial Meets Primary Endpoint
06/10 ViiV Healthcare’s long-acting HIV treatment Cabenuva (cabotegravir + rilpivirine) meets primary endpoint of superior viral suppression vs. daily oral therapy in people with viremia
05/10 European Equities Traded in the US as American Depositary Receipts Track Lower in Monday Trading
02/10 Major drugmakers turn to China for licensing deals
30/09 European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading
30/09 Major drugmakers turn to China for licensing deals
30/09 Wave Life Sciences Earns $12 Million Milestone as GSK Advances Liver Drug
30/09 Wave Life Sciences, Inc. Announces GSK?s Selection Of siRNA Program To Transition To GSK For Further Development
30/09 Lonza nominiert Pearl Huang für Verwaltungsrat - Mäder geht
29/09 Pharma sector doubles down on AI to slash costs, timelines
29/09 Stocks rise as oil prices edge down
29/09 FTSE 100 hits two-week low as energy stocks slide
29/09 WINNERS & LOSERS: Vesuvius soars on bid; Zigup lifts outlook
29/09 Stocks rise as pharma and miners advance
28/09 AN2 Therapeutics, Inc. Announces Extension of Funding for Tuberculosis Research Collaboration with GSK
28/09 AN2 Therapeutics Gets Gates Foundation Funding Extension for Tuberculosis Research
28/09 Hutchmed begins phase Ia trial of HMPL-A830 in China
28/09 Hutchmed Doses First Patient in Early-Stage Trial of HMPL-A830 for Solid Tumors
28/09 Landsec sells London office; Entain holds guidance
Aucun résultat pour cette recherche